A Randomised Single-Blind Study to Improve Health-related Quality of Life as Measured by the Short-Form 36 (SF-36) Vitality Score by Correcting Anemia With Aranesp (Darbepoetin Alfa) in the Elderly.

Trial Profile

A Randomised Single-Blind Study to Improve Health-related Quality of Life as Measured by the Short-Form 36 (SF-36) Vitality Score by Correcting Anemia With Aranesp (Darbepoetin Alfa) in the Elderly.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 04 Jul 2014

At a glance

  • Drugs Darbepoetin alfa (Primary)
  • Indications Anaemia
  • Focus Therapeutic Use
  • Acronyms STIMULATE
  • Sponsors Amgen
  • Most Recent Events

    • 20 May 2014 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
    • 12 Jan 2010 Actual patient number (51) added as reported by ClinicalTrials.gov.
    • 14 May 2008 The expected completion date for this trial has changed from September 2008 to May 2009 according to ClinicalTrials.gov
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top